Cathie Wood’s Portfolio: 5 Stocks Under $10

2. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Number of Hedge Fund Holders: 30

Share Price as of April 15: $3.84

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was founded in 2008 and is headquartered in Boston, Massachusetts. The biotech company operates a cell programming platform that is used in the chemicals, agriculture, food, consumer products, and pharmaceuticals markets. On April 5, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced an investment of $3.5 million in Microba Life Sciences’ initial public offering on the Australian Securities Exchange, subsequently acquiring a 4% position. 

Cathie Wood’s ARK Investment Management owns more than 43 million shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) as of Q4 2021, worth $358.8 million, representing 1.08% of the total 13F holdings. The hedge fund increased its stake in the company by 86% in the December quarter. 

On March 31, BTIG analyst Mark Massaro reiterated a Buy recommendation on Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) but slashed the firm’s price target on the stock to $6 from $12. The company’s Q4 results were better than expected and demand is historically at a record-high, the analyst told investors in a research note. 

According to Insider Monkey’s Q4 data, 30 hedge funds held long positions in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), with combined stakes of $4.2 billion, compared to 32 funds in the earlier quarter, holding stakes in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) worth $5.6 billion.